Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share (the "Shares")
-
Shares outstanding
-
94,401,153
-
Total 13F shares
-
16,164,902
-
Share change
-
+16,164,902
-
Total reported value
-
$463,124,000
-
Price per share
-
$28.65
-
Number of holders
-
49
-
Value change
-
+$463,124,002
-
Number of buys
-
49
Institutional Holders of Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) as of Q3 2018
As of 30 Sep 2018,
Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) was held by
49 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
16,164,902 shares.
The largest 10 holders included
Vivo Capital, LLC, FMR LLC, PERCEPTIVE ADVISORS LLC, ORBIMED ADVISORS LLC, RA CAPITAL MANAGEMENT, LLC, JANUS HENDERSON GROUP PLC, PRICE T ROWE ASSOCIATES INC /MD/, BlackRock Inc., Vanguard Group Inc, and Artal Group S.A..
This page lists
49
institutional shareholders reporting positions in this security
for the Q3 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.